Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. AUPH
AUPH logo

AUPH News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

AUPH News

Aurinia Pharmaceuticals CEO Acquires Shares Worth $12.5 Million

Jun 07 2026NASDAQ.COM

Aurinia CEO Kevin Tang Acquires 814,606 Shares

Jun 07 2026Fool

Director Paul J. Fribourg Acquires 273,500 Shares of IFF

Jun 03 2026NASDAQ.COM

Tang Capital Acquires Shares of Aurinia Pharmaceuticals

Jun 03 2026seekingalpha

Aurinia Reports 23% Revenue Growth in Q1

May 07 2026stocktwits

Aurinia Pharmaceuticals Reports Q1 Earnings Growth

May 07 2026NASDAQ.COM

Aurinia Pharmaceuticals Q1 Earnings Exceed Expectations

May 07 2026seekingalpha

Biotech Landscape Update: Regulatory Approvals and Acquisitions

Apr 03 2026NASDAQ.COM

AUPH Events

06/04 07:10
Aurinia Pharmaceuticals Presents New Analysis of Lupkynis at EULAR 2026
Aurinia Pharmaceuticals announced that a new analysis of the AURORA 1 Phase 3 study of Lupkynis in the treatment of lupus nephritis is being presented at the European Alliance of Associations for Rheumatology, EULAR, 2026 Congress. This new analysis on the safety population of 356 patients indicates that Lupkynis was associated with a statistically significant 53% reduction in the risk of renal-related event or death. Hazard ratios favored treatment with Lupkynis for the following individual components of the composite endpoint: death, treatment failure and worsening proteinuria.
06/03 09:00
Stock Futures Slightly Lower as Investors Digest Employment Data
Stock futures are slightly lower while investors digest stronger-than-expected employment data and wait for Friday's official nonfarm payrolls report. According to ADP, private-sector employers added 122,000 jobs in May, above the consensus forecast of 118,000 and up from the prior month's reading. Enthusiasm surrounding data-center spending, cloud infrastructure, semiconductors, and power-demand beneficiaries continues to support the broader indexes. However, investors have become increasingly selective, rewarding companies that can demonstrate tangible AI-related revenue growth while showing less patience for firms that are merely associated with the theme.Treasury yields are relatively stable. The 10-year Treasury yield remains elevated by recent standards, but the market has seemingly become more comfortable with the idea that rates may stay higher for longer.In pre-market trading, S&P 500 futures fell 0.22%, Nasdaq futures rose 0.04% and Dow futures fell 0.46%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Aurinia Pharmaceuticalsup 3% after disclosing the purchase of 206,005 shares by director Kevin TangUP AFTER EARNINGS -GameStopup 11%Destination XLup 6%Ollie's Bargain Outletup 5%Medtronicup 4%Macy'sup 2%DOWN AFTER EARNINGS -GitLabdown 6%Ulta Beautydown 3%Palo Alto Networksdown 2%LOWER -Circle Internetdown 2% afterthat Coinbaseis exploring participation in a new stablecoin platform
05/07 08:10
Aurinia CEO Emphasizes LUPKYNIS as Standard Treatment for Lupus Nephritis
"Aurinia remains steadfast in its mission to become a leading company that benefits patients suffering from autoimmune diseases," stated Kevin Tang, Chief Executive Officer. "LUPKYNIS is emerging as a standard-of-care treatment for lupus nephritis, and aritinercept, now in clinical development for three potential indications, has therapeutic potential across a wide range of autoimmune disorders."

AUPH Monitor News

No data

No data

AUPH Earnings Analysis

No Data

No Data

People Also Watch